Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the primary ways that multigene profiling is used in early stage breast cancer.

Multigene gene profiling, such as the Oncotype DX score, help determine treatment in patients that are estrogen receptor (ER) positive or progesterone receptor (PR) positive and HER2 neu negative with early stage cancers. The recurrence score is used most in node negative breast cancer because the patients with an intermediate to high recurrence score are a subset of early breast cancer patients that derive the most benefit from chemotherapy.

Videos

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Tripathy Discusses Breast Cancer Gene Profiling

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, describes the biomarkers used in clinical decision-making at the time of surgery for early stage breast cancer.

Tripathy describes estrogen receptor (ER), progesterone receptor (PR), and HER2 neu as mandatory in order to make decisions for invasive cancer, for in situ ER and PR are useful to determine if a hormonal therapy will be effective. Trastuzumab is currently being used for mostly all HER2 positive breast cancer with a few exceptions. If there is an expression of even 1% or more of either estrogen or progesterone it calls for the use of hormonal therapy.

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Dr. Tripathy Discusses Breast Cancer Biomarkers

Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 

28th Annual Miami Breast Cancer Conference

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases

Dr. Tripathy on Breast Cancer with Bone Metastases

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Dr. Tripathy on Bone Health in Breast Cancer Patients

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer. 

Debu Tripathy, MD,

Articles

Dr. Tripathy Discusses Breast Cancer Gene Profiling

Dr. Tripathy Discusses Breast Cancer Biomarkers

Dr. Tripathy on Breast Cancer with Bone Metastases

Dr. Tripathy on Bone Health in Breast Cancer Patients

Dr. Tripathy Discusses Bisphosphonate Studies